Faron Pharmaceuticals floats as lead product enters Phase III
This article was originally published in Scrip
Executive Summary
Turku, Finland-based Faron Pharmaceuticals has floated on the London Stock Exchange's Alternative Investment Market (AIM), raising £10m to fund a Phase III trial for its lead product, orphan drug Traumakine.